Engineering topics

Miller, Samuel

Publications and source records attributed to Miller, Samuel.

4 records

DOE OSTI2026

The High Rigidity Spectrometer at the FRIB: Magnet Development Status

This paper presents the 2025 progress of the High Rigidity Spectrometer (HRS) project at the Facility for Rare Isotope Beams (FRIB). We report on the construction and testing of the first-article HRS-High Transmission BeamLine (HTBL) magnets. An HTBL dipole magnet has successfully completed cold testing, achieving full magnetic performance without quenching, and is now ready for field mapping at FRIBs offline test bench. HTBL quadrupole triplet coils have been fabricated and tested, with all coils reaching their design currents, some following initial training quenches. Furthermore, the preliminary design of the large-scale, large-aperture SPectrometer Section (SPS) magnets has progressed to determine the baseline of the downstream HRS-SPS subproject in 2025. This includes the introduction of novel magnet designs, such as the sweeper dipole magnet, the sector dipole magnet, and iron-free coil-dominated quadrupole magnets, representing a significant scale breakthrough and a first for FRIB.

Choi, Yoonhyuck↗

DOE OSTI2025

Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity

ABSTRACT Dose-limiting toxicities pose a major barrier to cancer treatment. While preclinical studies show that the gut microbiota influences and is influenced by anticancer drugs, data from patients paired with careful side effect monitoring remains limited. Here, we investigate capecitabine (CAP)-microbiome interactions through longitudinal metagenomic sequencing of stool from 56 advanced colorectal cancer patients. CAP significantly altered the gut microbiome, enriching for menaquinol (vitamin K2) biosynthesis genes. Transposon library screens, targeted gene deletions, and media supplementation revealed that menaquinol biosynthesis protectsEscherichia colifrom drug toxicity. Stool menaquinol gene and metabolite levels were associated with decreased peripheral sensory neuropathy. Machine learning models trained in this cohort predicted toxicities in an independent cohort. Taken together, these results suggest treatment-associated increases in microbial vitamin biosynthesis serve a chemoprotective role for bacterial and host cells. Further, our findings provide a foundation for in-depth mechanistic dissection, human intervention studies, and extension to other cancer treatments. IMPORTANCE Side effects are common during the treatment of cancer. The trillions of microbes found within the human gut are sensitive to anticancer drugs, but the effects of treatment-induced shifts in gut microbes for side effects remain poorly understood. We profiled gut microbes in colorectal cancer patients treated with capecitabine and carefully monitored side effects. We observed a marked expansion in genes for producing vitamin K2 (menaquinone). Vitamin K2 rescued gut bacterial growth and was associated with decreased side effects in patients. We then used information about gut microbes to develop a predictive model of drug toxicity that was validated in an independent cohort. These results suggest that treatment-associated increases in bacterial vitamin production protect both bacteria and host cells from drug toxicity, providing new opportunities for intervention and motivating the need to better understand how dietary intake and bacterial production of micronutrients like vitamin K2 influence cancer treatment outcomes.

Microbiology↗

DOE OSTI2024

FRIB Beam Power Ramp-up: Status and Plans

After project completion on scope, on cost, and ahead of schedule, the Facility for Rare Isotope Beams began operations for scientific users in May of 2022. The ramp-up to a beam power of 400 kW is planned over a six-year period; 1 kW was delivered for initial user runs from in 2022, and 5 kW was delivered as of February 2023. Test runs with 10 kW 36Ar and 48Ca beams were conducted in July 2023. Upgrade plans include doubling the primary-beam energy to 400 MeV/nucleon for enhanced discovery potential (¿FRIB 400¿). This talk reports on the strategic plans towards high power operations emphasizing challenges and resolutions in beam-interception devices and targetry systems, radiation protection and controls, and legacy system renovation and integration.

43 PARTICLE ACCELERATORS↗

DOE OSTI2023

FRIB Transition to User Operations, Power Ramp Up, and Upgrade Perspectives

After project completion on scope, on cost, and ahead of schedule, the Facility for Rare Isotope Beams began operations for scientific users in May of 2022. During the first 12 months of user operations, the FRIB accelerator complex delivered 5250 beam hours, including 1528 hours to nine science experiments conducted with primary beams of 36Ar, 48Ca, 70Zn, 82Se, 124Xe, and 198Pt at beam energies >200 MeV/u; 2724 hours for beam developments, studies, and tuning; and 998 hours to industrial users and non-scientific programs using the FRIB Single Event Effect (FSEE) beam line. The ramp-up to a beam power of 400 kW is planned over a six-year period; 1 kW was delivered for initial user runs from in 2022, and 5 kW was delivered as of February 2023. Upgrade plans include doubling the primary-beam energy to 400 MeV/nucleon for enhanced discovery potential (¿FRIB 400¿). This talk reports on FRIB status and progress since SRF2021, emphasizing lessons learned during the transition from beam commissioning to machine operations, challenges and resolutions for the power ramp-up, progress with accelerator improvements, and R&D for the energy upgrade.

43 PARTICLE ACCELERATORS↗